(Nasdaq)
French biotech Valneva, which has developed a lineup of traveler vaccines and is starting a late-stage COVID vax effort, is seeking to level up to the Nasdaq with a $100 million IPO.
The company is currently listed on the Euronext in Paris as VLA but wants to move on over to the more lucrative U.S. markets, and comes at a time when after years of neglect, vaccine research is all the rage, and with a COVID asset in hand, Valneva the more interesting to investors.
Valneva already has a licensed vaccine portfolio includes Ixiaro, marketed as Jespect in Australia and New Zealand, for the prevention of Japanese encephalitis, as well as Dukoral to prevent cholera.
MedCity News
Achilles Therapeutics’ IPO nabs $175M to bring cell therapies to solid tumors
The Achilles Therapeutics IPO comes as several other biotechs make progress developing a type of cancer immunotherapy called a tumor-infiltrating lymphocyte. Clinical-stage Achilles contends its approach could best them all.
Shares0
FDA approval of cell therapies made from a patient’s own immune cells provided another treatment option for the most serious cases of blood cancer. But this type of treatment, called CAR-T therapy, is cumbersome to manufacture and still hasn’t proven effective in solid tumors.
A different type of cell therapy called tumor infiltrating lymphocytes (TIL) could offer yet another alternative, plus the potential to address solid tumors. Several biotechs have TILs in clinical development. Achilles Therapeutics aims to best them all.
Longboard Pharmaceuticals Announces Pricing of Initial Public Offering
March 11, 2021 21:44 ET | Source: Longboard Pharmaceuticals, Inc. Longboard Pharmaceuticals, Inc. San Diego, California, UNITED STATES
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $16.00 per share. The gross proceeds to Longboard from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $80.0 million.
Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GP
Prometheus Biosciences is taking a precision medicine approach to developing drugs and diagnostics for inflammatory bowel disease. The IPO cash will fund support its pipeline of IBD drug candidates for specific patient subpopulations.